Tag: NASDAQ:GDTC

CytoMed Therapeutics Limited (NASDAQ: GDTC) shares are witnessing a remarkable 19.42% surge in pre-market trading, climbing to $4.12. This significant uptick in GDTC stock followed the announcement of a pivotal collaboration agreement, positioning the company for promising advancements in cancer immunotherapy.

Groundbreaking Partnership with SunAct Cancer Institute

In order to investigate the therapeutic potential of CytoMed’s proprietary allogeneic gamma delta T cells, the company announced its signing of a Business & Research Collaboration Agreement (BRCA) with Mumbai-based SunAct Cancer Institute Private Limited, a well-known oncology-focused organization in India.

The collaboration includes a clinical research initiative, including a combined Phase 1 and Phase 2 investigator-led trial in India to evaluate the safety, tolerability, and effectiveness of these cells in treating various cancers, especially solid tumors.

The clinical trial will be jointly sponsored by CytoMed and SunAct, leveraging the expertise of SunAct’s medical team under the leadership of Dr. Vijay Patil, a distinguished oncologist and immunotherapy expert. In order to pave the way for revolutionary developments in cancer therapy, this expedited research project aims to determine the ideal dosage and assess preliminary safety and effectiveness characteristics.

Inexpensive Cancer Care in India

The partnership supports SunAct’s objective to provide affordable cancer treatments to a larger population in India, where cancer is a major burden. This collaboration aims to address both efficacy and affordability by utilizing the immune system’s capabilities to provide alternative treatment choices for a variety of solid malignancies.

This effort is further strengthened by the Central Drugs Standard Control Organization’s (CDSCO) favorable regulatory environment in India. The goal of financial incentives, like funding for cancer research, is to lower the costs of clinical research while promoting immunotherapy innovation. 

Leveraging Complementary Strengths

Under the BRCA, CytoMed will provide scientific expertise, technical support, and manufacturing capabilities for the investigational product. The collaboration taps into SunAct’s local knowledge of regulations, healthcare infrastructure, and patient demographics, creating a synergistic pathway to develop advanced cell-based allogeneic immunotherapies.

This partnership underscores CytoMed’s (GDTC) commitment to delivering affordable, off-the-shelf immunotherapies, potentially transforming cancer care and improving the quality of life for patients worldwide.

Shares of CytoMed Therapeutics Limited (NASDAQ: GDTC) are experiencing a significant uptick in the US stock market. As of the latest pre-market session, GDTC stock has risen by 17.65%, reaching $2.40. This surge follows the company’s announcement of multiple strategic developments.

Acquisition of Cellsafe International’s Assets

CytoMed, through its wholly owned subsidiary IPSC Depository Sdn Bhd, has acquired the license and certain assets of Cellsafe International Sdn Bhd (CISB). This acquisition, valued at approximately RM 2.3 million (US$ 490,000), was financed using internal cash resources.

CISB, a Malaysian cord blood bank currently in liquidation, offers CytoMed significant assets including a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment housing over 12,000 cord blood units (CBUs), and two freehold properties totaling 189 square meters.

CytoMed: Harnessing the Potential of γδ T Cells

With exclusive patents and expertise in γδ T cell technology, CytoMed aims to repurpose the cryopreserved CBUs globally, thus transforming the traditional business model of cord blood banking. The goal is to unlock the therapeutic potential of umbilical cord blood, enhancing the company’s strategic capital in developing cytotoxic γδ T cells for cancer treatment.

CytoMed aspires to lead in γδ T cell technology, producing viable γδ T cells from adult peripheral blood mononuclear cells, induced pluripotent stem cells (iPSCs), and eventually, cryopreserved CBUs.

Patent Award for iPSC-derived Hybrid γδ NKT Cells Technology

In another significant development, CytoMed has announced that the Intellectual Property Corporation of Malaysia has granted a patent for its licensed iPSC-derived hybrid γδ NKT cells technology, targeting both solid and hematological cancers.

This new patent expands CytoMed’s tumor-targeting therapy portfolio, complementing existing patents in Japan and China for the same technology. The patent award is timely, given Malaysia’s growing appeal to biomedical innovators amid an aging population and its reputation as a medical tourism hub.

CytoMed’s IPSC-γδ NKT cell program is actively progressing under GMP development, with animal studies set as the next milestone. Through these strategic initiatives, CytoMed Therapeutics Limited continues to advance its position in the field of cancer treatment, leveraging innovative technologies and expanding its intellectual property portfolio.